Moderna company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
A reported success in a late-stage melanoma treatment trial has helped lift Moderna’s stock, while an analyst estimate points to a long-term sales opportunity for the company’s personalized mRNA cancer approach.
THE APEX TIMES
THE APEX TIMES
Moderna’s stock fell on Thursday after a surge of up to 177% the prior day, as investors digested fresh momentum around its personalized cancer vaccine approach and analysts weighed the durability of the move.
THE APEX TIMES
Moderna’s stock fell in early trading following a record one-day surge, with investors citing profit-taking and lingering valuation concerns.
THE APEX TIMES
A sharp rally in Moderna stock followed news tied to a cancer-drug breakthrough, reviving the market focus on clinical evidence, regulatory next steps, and timelines.
THE APEX TIMES
The latest Zacks Investment Ideas installment highlighted Moderna and Merck in a broader healthcare-focused selection, drawing attention to the companies’ pipeline and commercial priorities, though the specific investment rationale was not detailed in the materials provided.
THE APEX TIMES
Bank of America raised its rating on Moderna to Neutral and set a $170 price target following a sharp rebound in the stock after the company reported positive results for its personalized cancer vaccine intismeran in adjuvant melanoma.
THE APEX TIMES
The Tesla and SpaceX CEO said messenger RNA could fundamentally change how diseases are treated, a remark that hit the same day as Moderna reported a cancer-vaccine breakthrough and its stock jumped sharply.
THE APEX TIMES
The biotech rally pushed Moderna toward the top end of S&P 500 stock performance for the year, according to market coverage, while cheering from prominent market commentators underscored investors’ appetite for cancer-related bets.
THE APEX TIMES
U.S. equity futures pointed to modest gains after a pullback in Treasury yields, with Moderna and Merck showing strength while investors appeared selective across sectors.
